ASND
NASDAQAscendis Pharma A/S
Price$261.38-1.17 (-0.44%)
01:30 PM07:45 PM
News · 26 weeks81-50%
2026-01-182026-07-12
Mix3690d
- Other14(39%)
- SEC Filings13(36%)
- Insider6(17%)
- Earnings2(6%)
- Analyst1(3%)
Latest news
25 items- SECSEC Form 6-K filed by Ascendis Pharma A/S6-K - Ascendis Pharma A/S (0001612042) (Filer)
- SECSEC Form 6-K filed by Ascendis Pharma A/S6-K - Ascendis Pharma A/S (0001612042) (Filer)
- PRChildren with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH TrialData presented during ICCBH 2026 showed that improvements in tibial-femoral angle (TFA), a measure of lower extremity alignment, continued through Week 104Greater improvements observed in children with preexisting genu varum (leg bowing) COPENHAGEN, Denmark, June 30, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced new radiographic data from Week 104 from the completed pivotal ApproaCH Trial of once-weekly TransCon CNP (navepegritide) in children with achondroplasia. In the trial, TransCon CNP-treated children demonstrated continued improvements in lower extremity alignment through up to two years of treatment, including improvements in tibial-femoral angle (TFA)
- SECSEC Form 6-K filed by Ascendis Pharma A/S6-K - Ascendis Pharma A/S (0001612042) (Filer)
- PRAscendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap®COPENHAGEN, Denmark, June 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that the Company has been added to the broad-market Russell 3000® Index, the large-cap Russell 1000® Index, the small-to-mid-cap Russell 2500® Index, and the Russell Midcap® Index as a part of the 2026 Russell U.S. Indexes semi-annual reconstitution, effective at the close of U.S. equity markets on June 26, 2026. The Russell 3000® Index tracks the largest 3,000 U.S. stocks, representing approximately 98% of investable U.S. equities by market capitalization. Within the Russell 3000®, the Russell 1000® Index comprises the 1,000 largest securities, representing more than 90% of investable
- PRAscendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026COPENHAGEN, Denmark, June 25, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that the latest data from its clinical development programs for the treatment of children with achondroplasia will be shared in an oral presentation and two posters at ICCBH 2026, the 12th International Conference on Children's Bone Health being held in Montreal from June 27-30. The data include an oral presentation of Week 104 data showing improvements in lower-extremity alignment from the recently completed pivotal ApproaCH Trial of TransCon® CNP (navepegritide) by Leanne Ward, M.D., Professor of Pediatrics in the Faculty of Medicine at the University of Ottawa (Canada), as well as a
- SECSEC Form 6-K filed by Ascendis Pharma A/S6-K - Ascendis Pharma A/S (0001612042) (Filer)
- SECSEC Form 6-K filed by Ascendis Pharma A/S6-K - Ascendis Pharma A/S (0001612042) (Filer)
- PRPhase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with HypoparathyroidismMulti-organ system and quality-of-life benefits sustained through three and a half years 86% response rate for the multi-component endpoint 89% of patients completed the three-and-a-half-year trial COPENHAGEN, Denmark, June 13, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced Week 182 data from its completed Phase 3 PaTHway Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) demonstrated sustained efficacy and safety in adults with hypoparathyroidism. Over the three-and-a-half-year duration of the trial, TransCon PTH replicated the systemic actions of endogenous PTH, with a balanced, beneficial impact on the main target organ systems –
- SECSEC Form 6-K filed by Ascendis Pharma A/S6-K - Ascendis Pharma A/S (0001612042) (Filer)
- PR5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism– Multi-organ system and quality-of-life benefits sustained through five years of treatment – 82% response rate for the multi-component endpoint – 95% of patients completed five years of treatment COPENHAGEN, Denmark, June 11, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced 5-year (Week 266) data from its Phase 2 PaTH Forward Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) demonstrated sustained efficacy and safety in adults with hypoparathyroidism. Over the five-year duration of the trial, TransCon PTH replicated the systemic actions of endogenous PTH, with a balanced, beneficial impact on the main target organ systems – kidney
- SECSEC Form 6-K filed by Ascendis Pharma A/S6-K - Ascendis Pharma A/S (0001612042) (Filer)
- PRAscendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026COPENHAGEN, Denmark, June 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that the latest data from its Endocrinology Rare Disease programs in hypoparathyroidism, achondroplasia, and pediatric growth hormone deficiency will be shared in two oral presentations and three posters at ENDO 2026, the annual meeting of the Endocrine Society being held in Chicago from June 13-16, 2026. "As a leader in rare endocrine diseases, we are committed to sharing comprehensive clinical trial results in peer-reviewed forums that reinforce the transformative potential of our innovative therapies," said Aimee Shu, M.D., Executive Vice President, Chief Medical Officer at Ascendis
- INSIDEREVP & Chief Financial Officer Smith Scott Thomas bought $21,900 worth of Ordinary Shares (100 units at $219.00), increasing direct ownership by 2% to 4,367 units (SEC Form 4)4 - Ascendis Pharma A/S (0001612042) (Issuer)
- INSIDERDirector Bienaime Jean Jacques bought $111,562 worth of Ordinary Shares (500 units at $223.12), increasing direct ownership by 125% to 900 units (SEC Form 4)4 - Ascendis Pharma A/S (0001612042) (Issuer)
- INSIDEREVP & Chief Financial Officer Smith Scott Thomas bought $55,830 worth of Ordinary Shares (250 units at $223.32), increasing direct ownership by 6% to 4,267 units (SEC Form 4)4 - Ascendis Pharma A/S (0001612042) (Issuer)
- INSIDERAmendment: New insider Smith Scott Thomas claimed ownership of 4,017 units of Ordinary Shares (SEC Form 3)3/A - Ascendis Pharma A/S (0001612042) (Issuer)
- INSIDERDirector Bienaime Jean Jacques bought $95,120 worth of Ordinary Shares (400 units at $237.80) (SEC Form 4)4 - Ascendis Pharma A/S (0001612042) (Issuer)
- SECSEC Form SD filed by Ascendis Pharma A/SSD - Ascendis Pharma A/S (0001612042) (Filer)
- ANALYSTCitigroup initiated coverage on Ascendis Pharma with a new price targetCitigroup initiated coverage of Ascendis Pharma with a rating of Buy and set a new price target of $355.00
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Ascendis Pharma A/SSCHEDULE 13G/A - Ascendis Pharma A/S (0001612042) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Ascendis Pharma A/SSCHEDULE 13G/A - Ascendis Pharma A/S (0001612042) (Subject)
- SECSEC Form 6-K filed by Ascendis Pharma A/S6-K - Ascendis Pharma A/S (0001612042) (Filer)
- INSIDEROfficer Jensen Flemming Steen sold $4,641,021 worth of Ordinary Shares (19,460 units at $238.49), closing all direct ownership in the company (SEC Form 4)4 - Ascendis Pharma A/S (0001612042) (Issuer)
- SECSEC Form 6-K filed by Ascendis Pharma A/S6-K - Ascendis Pharma A/S (0001612042) (Filer)
ASND FAQ
7 questionsWhat does Ascendis Pharma A/S do?
Ascendis Pharma A/S, a biopharmaceutical company, develops therapeutics for unmet medical needs. The company develops TransCon growth hormone, which completed Phase III clinical trials for growth hormone deficiency. It also develops TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for achondroplasia. In addition, the company develops preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. The company was incorporated in 2006 and is headquartered in Hellerup...Where does ASND stock trade?
Ascendis Pharma A/S (ASND) is listed on NASDAQ.What sector and industry is ASND in?
Ascendis Pharma A/S operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Ascendis Pharma A/S go public?
Ascendis Pharma A/S (ASND) completed its IPO in 2015.What are analysts saying about ASND?
Ascendis Pharma A/S has had 8 recent analyst actions on file. The most recent action was from Citigroup: Buy on 2026-05-19.What companies are similar to ASND?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ASND side-by-side with any of them on Quantisnow.How can I track ASND on Quantisnow?
Quantisnow aggregates Ascendis Pharma A/S's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ASND to receive live email and push alerts on every new disclosure.